Preeclampsia (PE) is a disorder associated with maternal hypertension, endothelial dysfunction and reductions in renal hemodynamics. Placental ischemia leads to increases in circulating maternal anti-angiogenic and pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) that induce endothelin-1 (ET-1), a potent vasoconstrictor. PE is also associated with depletion of nitric oxide, a facilitator of vasodilation, which binds to soluble guanylate cyclase (sGC), and synthesizes cGMP. In addition to promoting vasodilation, sGC activators and stimulators inhibit smooth muscle proliferation, leukocyte recruitment and platelet aggregation and are therefore, currently in clinical trials for treating cardiopulmonary disease. Although it is known that activating the nitric oxide signalling pathway induces vasodilation, its ability to inhibit TNF-α induced renal glomerular endothelial ET-1 production is unknown. We tested the hypothesis that cinaciguat, a sGC activator, attenuates ET-1 production induced by TNF-α in conditionally immortalized human glomerular endothelial cells. Cells were cultured; starved for 48 h; and treated for 12 h resulting in the following 4 groups having N=6/group: 1) Untreated, 2) 10 ng TNF-α 3) 10 μM cinaciguat + 10 ng TNF-α, and 4) 20 μM cinaciguat + 10 ng TNF-α. TNF-α (10 ng, 67.25±3.2 pg/mL) significantly increased ET-1 production compared to the untreated group (43.6±4.3 pg/mL, P<0.01). Interestingly, both cinaciguat treatment groups attenuated TNF-α induced ET-1 production, with significant reductions at a higher dose (20 μM, 57.38±1.42 pg/mL, P=0.02; 10 μM, 58.6±2.32 pg/mL, P=0.07). The results of this study demonstrate that activating sGC can attenuate ET-1 production. In conclusion, these findings suggest there is a therapeutic potential for treating preeclampsia with sGC activators.